Kos Pharmaceuticals, Inc (KOSP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DD™ who started this subject	10/7/2002 10:17:16 PM
From: mopgcw	Read Replies (1) of 118

Kos Pharmaceuticals Files SNDA For Niaspan DOW JONES NEWSWIRES MIAMI -- Kos Pharmaceuticals Inc. (KOSP) submitted a supplemental new drug application to the Food and Drug Administration to expand the labeling of Niaspan to include cutting the risk of strokes and "ministrokes." Niaspan is the only FDA-approved once-daily formulation of niacin for the treatment of lipid disorders. It is also indicated for the secondary prevention of heart attacks, and in combination with a bile-acid binding resin, to promote regression of coronary atherosclerosis in patients with high cholesterol. In a press release Monday, the pharmaceutical company said it is seeking to expand the current Niaspan label to include reducing the risk of stroke or transient ischemic attack - sometimes referred to as ministrokes - in patients with a previous heart attack and elevated cholesterol levels. Shares of Kos Pharmaceuticals traded recently at $11.87, up 38 cents, or 3.3%, on Nasdaq volume of 35,600 shares. Average daily volume is 114,107 shares.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next